The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq rallied strongly this week, with both now trading above all key moving averages including the 200-DMA (S&P 500: 3,958; Nasdaq: 11,507). This level will now act as initial near-term support until other shorter-term moving averages rise above. The next level of resistance on the S&P 500 is 4,100 to 4,119, while the Nasdaq’s next test is its September high of 12,270. The distribution day count remains at three and two, respectively.
Author: Raj Gupta
O’Neil Health Care Weekly
XLV fell 1.1% last week, continuing to underperform the broader market and leading to another low in its Relative Strength
line. This lag continues to warrant an equal to underweight sector positioning. On an absolute basis, support is now at
the 200-DMA ($130.97).
Market View
The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq shook out below their respective 50-DMA (S&P 500: 3,929; Nasdaq: 10,908) Thursday, before strongly regaining that level Friday. The S&P 500 now faces a range of resistance between 4,015 to 4,100, while the Nasdaq has resistance from ~11,492 to its rolling 200-DMA (11,567). The distribution day count stands at three and two, respectively.
O’Neil Health Care Weekly
XLV traded relatively flat for a 4th straight week, falling 16bps and again underperforming the broader market. Its RS line continues to fall, warranting an equal to underweight sector positioning. On an absolute basis, there is support at ~$133 to $134, before the 200-DMA.
Market View
The U.S. market remains in a Confirmed Uptrend. The S&P 500 narrowly regained its 200-DMA (3,981) this week, with the next level of resistance at 4,100. The Nasdaq regained its 50-DMA (10,866) and is now testing resistance at the falling 100-DMA (11,058). The distribution day count remains unchanged at two and one, respectively.
Health Care Conference
Key points from this report:
- Ideas are showing positive technical trends, holding above key price and/or moving average support.
- Ideas also have positive fundamental ratings and rankings and/or accelerating annual EPS growth.
- Included are 20 annotated charts.
O’Neil Health Care Weekly
XLV fell 13bps last week, underperforming the S&P 500 and Nasdaq. This lag resulted in its Relative Strength line (vs. the S&P 500 or Nasdaq) ticking lower for the first time since early November which warrants a slight reduction in sector weight. There is support at $133.71, followed by the 200-DMA at $131.08. Resistance remains $140 to $142.
Market View
The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq closed the week strong, with the Nasdaq staging a Day 6 follow-through day Friday. The S&P 500 is now trading just below 50-DMA (3,904) resistance, while the Nasdaq faces resistance at its 21-DMA (10,627) before the 50-DMA (10,873). The distribution day count stands at two and one, respectively.
O’Neil Health Care Weekly
XLV fell 17bps last week, in-line with the S&P 500 which kept its relative strength (RS) line at new highs. The sector is
now testing 50-DMA ($134.62) support with the next level below this at the flattening 200-DMA ($131.11). Resistance
remains ~$140 to $142. With an RS line remaining at new highs, an overweight sector positioning remains warranted.
Market View
The U.S. market is in a Confirmed Uptrend. The S&P 500 staged a Day 5 follow-through Thursday, resulting in a rules-based upgrade of the market status. To remain intact, the S&P 500 should hold the December 22 low of 3,764. Despite the move and subsequent upgrade, there remain multiple levels of near-term resistance, including the 10- 21-, 50-, and 100-DMA, which are trading between 3,851 and 3,903. Further, the Nasdaq has yet to stage a FTD, still trading just 3% from year-to-date lows. The earliest a FTD can take place on this index is Wednesday. The 50-DMA (10,911) remains primary resistance despite the 10- and 21-DMA now trading below that level.